Humanized CAR19T2 T Cell in Children With Refractory/Relapsed B-cell Leukemia/Lymphoma
This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor-T cell (CAR19T2 T cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.
An open single arm clinical study of combination of CFR64 T and anti-CD20 monoclonal antibodies for relapsed and refractory B-cell lymphoma
/ Not yet recruitingPhase 1IIT Phase I clinical trial of CAR-T cell therapy targeting glycoprotein after failed first-line treatment of recurrent and metastatic nasopharyngeal carcinoma
100 Clinical Results associated with Guangdong Zhaotai Cell Biotechnology Co., Ltd
0 Patents (Medical) associated with Guangdong Zhaotai Cell Biotechnology Co., Ltd
100 Deals associated with Guangdong Zhaotai Cell Biotechnology Co., Ltd
100 Translational Medicine associated with Guangdong Zhaotai Cell Biotechnology Co., Ltd